51 results about "Extended release" patented technology

A nanoparticle-well treatment additive complex comprising an amine functionalized silica nanoparticle, and a well treatment additive, where the well treatment additive is releasably attached to an amine group of the amine functionalized silica nanoparticle is disclosed. Methods of using the amine functionalized silica nanoparticle is also disclosed.

Disclosed are a pharmaceutical composition comprising a compound of formula (I) as an active ingredient for inhibiting JAK, or treating JAK-mediated disease or disorder, a process for preparing the same and use of the same. The pharmaceutical composition has an advantage of high dissolution, and further has one or more advantages such as extended release, good pharmacokinetic properties.

The invention relates to the technical field of medical instruments, in particular to a targeted balloon coating capable of prolonging the release period in a dynamic environment and a preparation method of the targeted balloon coating. The renaturable xerogel can be quickly rehydrated after being dried, and a temporary membrane is formed on the inner wall of a blood vessel to resist blood flow scouring. The exosome enhances the vascular endothelium targeting through RGD peptide targeted modification. The polydopamine-hyaluronic acid composite adhesion coating improves the flexibility and adhesion of the coating. Therefore, the drug retention rate within 1 hour after expansion is greater than or equal to 85%, and the vascular endothelium uptake efficiency of the RGD modified exosome is improved by 3 times.

Provided herein are polymer compositions and extended release otic agents. In one aspect, provided herein is a polymer composition including about 5% to about 15% by weight of the polymer composition of a functional polymer, wherein the functional polymer includes a first functional group, about 0.05% to about 0.6% by weight of the polymer composition of a crosslinker, wherein the crosslinker includes a second functional group, and water, wherein a crosslinking reaction can occur between the first functional group and the second functional group to form a gel, and wherein the polymer composition has a gelation time of about 45 seconds to about 60 minutes at a temperature of about 20° C.

A composition for oral administration of gamma aminobutyric acid (GABA), the composition comprising: GABA; at least one retention agent configured to increase retention of the composition, and the GABA contained in the composition, in the stomach for an extended period of time; and at least one slow release agent configured to allow extended release of the GABA from the composition. Additional embodiments of the composition, it method of administration and its use are disclosed herein.

The disclosure pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the disclosure have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended-release configuration or a sustained release carrier.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

The present invention provides a liposomal pharmaceutical formulation for subcutaneous or intravenous administration of antibodies, comprising one or more phospholipids; one or more antibodies; and a pharmaceutically acceptable vehicle, wherein the one or more phospholipids form liposomes that encapsulate the one or more antibodies, wherein the liposomes have a polydispersity index (PDI) below 0.2 and at least 90% of the liposomes have a size less than 125 nm.

We disclose here the nano-enabled delivery of highly potent 5-hydroxymethyl furfural (5-HMF) to sickled blood cells in patients. 5-HMF, a superior antisickling agent, has been formulated to address the limitations of existing treatment modalities arising from disfavorable pharmacokinetics of the drug compound. Specifically, two complementary 5-HMF prodrugs are integrated as a ‘protected’ biocompatible composite nanoparticle designed to readily fuse with RBCs and be amenable to transdermal delivery (5-HMF-grafted-phospholipid layered over a sucrose-derived graphitic carbon dot core). These RBC-targeted, protected, biocompatible, self-assembled 5-HMF prodrug nanoparticles for sickle cell disease are the first in class technology for offering a treatment for sickle cell disease which has improved potency, targeted payload delivery, and extended release with the red blood cells with enhanced pharmacodynamic effect in a treated patient.

The present invention relates to an injectable formulation, a method for treating a metabolic disease and an administration device. The injectable formulation comprises a lipid matrix composition, a specific amount of a GLP-1 receptor agonist and at least one pharmaceutically acceptable ion. Accordingly, upon contacting an aqueous fluid, the injectable formulation forms a depot exhibiting an extended release of the GLP-1 receptor agonist in vivo or in vitro. In the method for treating the metabolic disease, the injectable formulation can be administered to a subject with a reduced dosing frequency, and it is not necessary to store the injectable formulation for the next administration. For the administration device, the injectable formulation is filled in a vial, a pre-filled syringe or a pre-filled cartridge. Therefore, the injectable formulation can be designed for a single use, thereby enhancing convenience, compliance and adherence of a subject.

The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

Long-acting resorbable subcutaneous implant with extended release of pre-concentrated pharmacologically active substance in polymer for treatment of chronic adrenal insufficiency. The implant is inserted subcutaneously and has continuous release of the active ingredient for an extended period of time. The implant may have in its constitution only hydrocortisone but is preferably formed by hydrocortisone particles homogeneously dispersed in a bio erodible and bioabsorbable polymer matrix. Such a polymer matrix may be formed of a polymer or a polymer blend. The release of the drug in this system occurs through diffusion, at a relatively constant rate, and it is possible to change the rate of release of the drug through the thickness or material of this membrane.

The present invention relates to extended release composition of Mirabegron and process of manufacture thereof. The extended release composition of mirabegron comprising non-polymeric hydrophobic excipient as release controlling agent along with one or more pharmaceutically acceptable excipient is used in the treatment of symptoms associated with overactive bladder.

An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile. Dosage units may also provide an immediate release component.

Drug delivery systems comprising a floating interpenetrating network (IPN) are provided. The pharmaceutical compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent, such that upon oral ingestion of the compositions, a floating IPN is formed in situ. These floating IPN provide extended release of the drug entrapped therein for at least about 3 hours.

The present disclosure generally relates to hydrophobic salts of hydrophilic peptides that form low-solubility materials in aqueous solutions and are capable of extended or sustained release of peptide components when administered to a subject. Hydrophobic salts of C-type natriuretic peptides and uses thereof are also disclosed. The present disclosure relates to compositions comprising salts of electrostatically charged peptides that have low solubility in solution, such that the salts form solid or semi-solid forms in aqueous media. It is shown herein that such salts dissolve more slowly than the non-salt forms of the peptides in aqueous solutions and can be used in extended-release therapeutics without the need for reformulation in typical extended-release formats.

The present invention relates to pharmaceutical formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide, or a pharmaceutically acceptable salt thereof, for extended release, to methods for preparation thereof, and to uses thereof for treatment of pain or providing peri-operative anesthesia or post-operative analgesia.

The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.

Extended release or long-acting injectable compositions for use as in-situ forming implants are provided. The extended release injectable compositions and resulting long-acting in-situ forming implants include one or more drugs or active agents, a biocompatible solvent, a biodegradable polymer, and either an amphiphilic additive or a hydrophobic additive, or a combination of an amphiphilic additive and a hydrophobic additive. Such compositions are made to be injected in subjects in need of treatment to form in-situ formed implants within the subject, such in-situ formed implants having increased drug load and improved drug release for a longer duration. Methods of using such compositions, and treating subjects therewith are provided. Methods of making such compositions are also provided.

Provided herein are polymer compositions and extended release otic agents. In one aspect, provided herein is a polymer composition including about 5% to about 15% by weight of the polymer composition of a functional polymer, wherein the functional polymer includes a first functional group, about 0.05% to about 0.6% by weight of the polymer composition of a crosslinker, wherein the crosslinker includes a second functional group, and water, wherein a crosslinking reaction can occur between the first functional group and the second functional group to form a gel, and wherein the polymer composition has a gelation time of about 45 seconds to about 60 minutes at a temperature of about 20° C.

Disclosed herein are injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 for an extended release of DFO nanochelators. Methods of manufacture and of use are also provided.

To provide longer-acting forms of C-type natriuretic peptide (CNP) and analogs thereof in more convenient forms for the treatment of various conditions and diseases, such as dwarfism and achondroplasia, which allow maintenance of therapeutic levels of peptide between administrations so as to provide therapeutic peptide levels for a sufficient time in a daily administration schedule without the need for overdosing.SOLUTION: Provided herein are extended release hydrogel conjugates of c-natriuretic peptides, methods of preparation thereof, and methods of use thereof.SELECTED DRAWING: None

Provided herein are pharmaceutical compositions comprising midazolam and ketamine, and methods of inducing sedation (e.g., procedural sedation) in a subject using administration of such compositions, the compositions optionally including a pharmaceutically active compound of a third class. Compositions may be in sublingual or buccal form, or incorporated into vehicles for extended release. Methods for fabricating the compositions and using them for anesthesiological applications are also described.

Disclosed is a complex including: cellulose nanocrystals; at least one β-cyclodextrin molecule; and at least one curcumin molecule, suitable for use in the treatment of any kind of peripheral neuropathies. Further disclosed is a pharmaceutical composition including at least the complex and at least one pharmaceutically acceptable excipient. Also disclosed is the use of the complex or the pharmaceutical composition, in particular in the form of a hydrogel, a subcutaneous implant, an implantable pump, an implanted biofunctionalized nerve conduit, to improve the treatment compliance, to allow an extended release of the complex and to obtain better pharmacokinetics.

The present disclosure provides a kirigami-inspired injectable stent system. The stent systems and methods enable radial / circumferential and longitudinal delivery of an extended release of therapeutics within tubular structures of the body, such as the GI tract and trachea. According to some aspects, a kirigami-based injectable stent system is provided that can enable drug release through deposition of therapeutic-coated needles of the stent in the tubular mucosa, such as often found in the gastrointestinal tract or trachea.

Described is an extended release pharmaceutical composition. The composition comprises a therapeutically effective amount of an active agent selected from the group consisting of ketamine, norketamine, pharmaceutically acceptable salts thereof, and combinations thereof. The active agent is incorporated into a sustained-release polymeric matrix. The matrix comprises a matrix polymer, and a permeability-modifying filler. A method of preventing, treating and / or managing treatment-resistant depression in a subject is also or alternatively describe.

The invention discloses a composition containing an immediate release delivery composition and a sustained release delivery composition as well as a preparation method and application of the composition. The quick-release delivery composition contains alpha-ketoglutaric acid or pharmaceutically acceptable salts thereof, can quickly release alpha-ketoglutaric acid or pharmaceutically acceptable salts thereof in a gastrointestinal tract pH environment, and has a good application prospect in the large health industry, such as health care products, food or drugs. The medicine composition is simple in preparation method, good in smoothness and suitable for large-scale production.

Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.

Described herein are tough gel compositions that comprise an interpenetrating networks (IPN) hydrogel. The IPN hydrogel comprises a first polymer network (covalently crosslinked) and a second polymer network (ionically crosslinked), at least one therapeutic agent, and a clay material. The tough gel compositions may further include an adhesive polymer layer attached to the IPN hydrogel. Methods of use of these compositions, such as for extended release drug delivery, are also described.

The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.